ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy

ACTG 260 was an open-label, four-arm trial designed to study the safety and anti-human immunodeficiency virus (anti-HIV) activity of delavirdine monotherapy at three ranges of concentrations in plasma compared to those of control therapy with zidovudine or didanosine. Delavirdine doses were adjusted...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Para, Michael F., Meehan, Patricia, Holden-Wiltse, Jeanne, Fischl, Margaret, Morse, Gene, Shafer, Robert, Demeter, Lisa M., Wood, Kenneth, Nevin, Tom, Virani-Ketter, Nzeera, Freimuth, William W.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 1999
Teme:
Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC89281/
https://ncbi.nlm.nih.gov/pubmed/10348755
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items